QIFENG
873169
Jin Tong Ling Technology Group
300091
Jinlong Machinery & Electronic
300032
4
Qingdao Gaoce Technology
688556
5
Aerospace Nanhu Electronic Information Technology
688552
US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 34.850
- -0.010-0.03%
Close May 7 16:00 ET
- 34.830
- -0.020-0.06%
Pre 05:44 ET
5.53BMarket Cap139.40P/E (TTM)
35.473High34.220Low3.59MVolume34.940Open34.860Pre Close124.67MTurnover2.42%Turnover Ratio232.33P/E (Static)158.78MShares46.48052wk High23.33P/B5.16BFloat Cap15.16052wk Low--Dividend TTM148.20MShs Float149414.006Historical High--Div YieldTTM3.59%Amplitude0.956Historical Low34.763Avg Price1Lot Size
TG Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 90.40%120.86M | 40.80%329M | 146.04%108.19M | -49.41%83.88M | 357.05%73.47M | 713.46%63.47M | 8,290.02%233.66M | 54,863.75%43.97M | 176,298.94%165.82M | 2,606.06%16.07M |
| Operating revenue | 90.40%120.86M | 40.80%329M | 146.04%108.19M | -49.41%83.88M | 357.05%73.47M | 713.46%63.47M | 8,290.02%233.66M | 54,863.75%43.97M | 176,298.94%165.82M | 2,606.06%16.07M |
| Cost of revenue | 185.63%15.54M | 172.35%38.49M | 96.07%15.4M | 166.20%9.34M | 334.54%8.3M | 534.89%5.44M | 5,232.45%14.13M | 261,700.00%7.85M | 175,350.00%3.51M | 8,208.70%1.91M |
| Gross profit | 81.47%105.32M | 32.34%290.52M | 156.90%92.79M | -54.08%74.54M | 360.09%65.16M | 735.49%58.03M | 8,611.55%219.53M | 46,805.19%36.12M | 176,319.57%162.31M | 2,380.39%14.16M |
| Operating expense | 43.67%96.69M | 24.98%248.59M | 29.29%62.84M | 30.68%62.1M | -4.23%56.35M | 53.18%67.3M | -9.93%198.9M | -37.38%48.6M | 35.56%47.52M | 48.91%58.84M |
| Selling and administrative expenses | 45.55%50.33M | 25.75%154.3M | 25.07%38.96M | 28.07%41.97M | 26.29%38.79M | 23.20%34.58M | 28.51%122.71M | -35.07%31.15M | 129.89%32.77M | 143.04%30.72M |
| -General and administrative expense | 45.55%50.33M | 25.75%154.3M | 25.07%38.96M | 28.07%41.97M | 26.29%38.79M | 23.20%34.58M | 28.51%122.71M | -35.07%31.15M | 129.89%32.77M | 143.04%30.72M |
| Research and development costs | 41.68%46.36M | 23.75%94.29M | 36.82%23.87M | 36.50%20.14M | -37.57%17.56M | 106.19%32.72M | -39.22%76.19M | -41.12%17.45M | -29.08%14.75M | 4.64%28.12M |
| Operating profit | 193.01%8.62M | 103.21%41.93M | 339.88%29.95M | -89.17%12.43M | 119.73%8.82M | 74.94%-9.27M | 109.45%20.63M | 83.90%-12.49M | 428.30%114.78M | -14.72%-44.67M |
| Net non-operating interest income expense | -195.32%-6.76M | -90.47%-24.03M | -190.46%-7.06M | -191.73%-10.83M | -9.65%-3.98M | 19.55%-2.29M | -23.79%-12.62M | 15.06%-2.43M | -125.30%-3.71M | -20.22%-3.63M |
| Non-operating interest expense | 195.32%6.76M | 90.47%24.03M | 190.46%7.06M | 191.73%10.83M | 9.65%3.98M | -19.55%2.29M | 23.79%12.62M | -15.06%2.43M | 125.30%3.71M | 20.22%3.63M |
| Other net income (expense) | 309.43%3.6M | 52.52%7.69M | 188.20%2.57M | -6.75%2.67M | 147.76%1.71M | 45.70%880K | 7.43%5.04M | -53.89%890K | 260.53%2.86M | -52.28%691K |
| Other non- operating income (expenses) | 309.43%3.6M | 52.52%7.69M | 188.20%2.57M | -6.75%2.67M | 147.76%1.71M | 45.70%880K | 7.43%5.04M | -53.89%890K | 260.53%2.86M | -52.28%691K |
| Income before tax | 151.21%5.47M | 95.94%25.59M | 281.47%25.45M | -96.25%4.27M | 113.76%6.55M | 72.78%-10.68M | 105.84%13.06M | 82.13%-14.03M | 418.08%113.93M | -17.53%-47.61M |
| Income tax | 1,306.90%408K | 466.92%2.21M | 444.10%2.12M | 388K | -328K | 29K | 390K | 390K | 0 | 0 |
| Net income | 147.26%5.06M | 84.52%23.38M | 261.84%23.33M | -96.59%3.88M | 114.45%6.88M | 72.71%-10.71M | 105.66%12.67M | 81.63%-14.42M | 418.08%113.93M | -17.53%-47.61M |
| Net income continuous Operations | 147.26%5.06M | 84.52%23.38M | 261.84%23.33M | -96.59%3.88M | 114.45%6.88M | 72.71%-10.71M | 105.66%12.67M | 81.63%-14.42M | 418.08%113.93M | -17.53%-47.61M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 147.26%5.06M | 84.52%23.38M | 261.84%23.33M | -96.59%3.88M | 114.45%6.88M | 72.71%-10.71M | 105.66%12.67M | 81.63%-14.42M | 418.08%113.93M | -17.53%-47.61M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 147.26%5.06M | 84.52%23.38M | 261.84%23.33M | -96.59%3.88M | 114.45%6.88M | 72.71%-10.71M | 105.66%12.67M | 81.63%-14.42M | 418.08%113.93M | -17.53%-47.61M |
| Basic earnings per share | 142.86%0.03 | 77.78%0.16 | 260.00%0.16 | -96.25%0.03 | 114.71%0.05 | 75.00%-0.07 | 105.45%0.09 | 74.36%-0.1 | 407.69%0.8 | -13.33%-0.34 |
| Diluted earnings per share | 142.86%0.03 | 66.67%0.15 | 250.00%0.15 | -97.26%0.02 | 111.76%0.04 | 75.00%-0.07 | 105.45%0.09 | 74.36%-0.1 | 380.77%0.73 | -13.33%-0.34 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025